A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Study summary

The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedLY3200882 and Pembrolizumab

The study team can explain what participation involves.

Who it may be forAdvanced Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 19, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Eli Lilly and Company

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Eli Lilly and Company
Interventions being studied: Drug: LY3200882; Drug: Pembrolizumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Participants must have received a PD-1 PDLI therapy within 9 weeks of starting dosing on this study \[for example, nivolumab, pembrolizumab, atezolizumab\]
Participants must be willing to have tumor biopsies
Participants must have adequate organ function
Participants must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
Participants must be able to swallow tablets
Participants with stable, previously treated brain metastases may participate if neurologic symptoms have resolved and participants have been off steroids for at least 14 days

Reasons someone may not be able to joinExclusion criteria

Participants must not have moderate or severe cardiovascular disease
Participants must not have active autoimmune disease (for example Crohn's disease, Hashimotos disease, etc)
Participants must not have an active infection requiring treatment

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Dana Farber Cancer InstituteBoston, Massachusetts
CHU de Besancon Hopital Jean MinjozBesançon
Gustave RoussyVillejuif
Institut Catala d'OncologiaL'Hospitalet de Llobregat, Barcelona
Hospital Clinic I ProvincialBarcelona
Hospital Madrid Norte SanchinarroMadrid

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 19, 2020. Always confirm current availability with the study team.

View original record ↗